mRNA expression
Gene:
MAGEA2 (official gene symbol)Other symbol:
MAGEA2CT family:
CT1CT identifier:
CT1.2Aliases from NCBI:
MAGE2 , MAGEA2A , MGC131923Unified entry for genes MAGEA2, MAGEA2B (nearly-identical copies)
Gene expression pattern ? : Testis-restricted
High-throughput data (expression in cancer samples)
SAGE(short, 10 nt tags) Show
SAGE(long, 17 nt tags) Show
MPSS (short, 13 nt tags) Show
EST Show
Validation by Ludwig Institute of Cancer Research of mRNA expression in normal tissues and cell lines (RT-PCR)
Show![]() | ||
![]() | ||
The figures shown in this section represent a standardized analysis of all reported CT-antigens in the same set of mRNA preparations from
normal human tissues and a selection of human cancer cell lines. The analysis was done by RT-PCR using the primer pairs indicated for each gene.
A total of 1.0 �g of RNA was reverse-transcribed into cDNA using the Omniscript RT kit (Qiagen, Valencia, CA) using oligo (dT)18 primers
(Invitrogen, Carlsbad, CA). JumpStart REDTaq� ReadyMix-(Sigma Aldrich, St. Louis,MO) was used for amplification according to the manufacturer's
instructions. Samples were amplified with a precycling hold at 95oC for 3 min, followed by 35 specific cycles of denaturation at 95oC
for 15 seconds,annealing for 30 seconds (10 cycles at 60oC, 10 cycles at 58oC and 15 cycles at 56oC) and extension at 72oC for 30 seconds followed by a final
extension step at 72oC for 7 minutes. The RT-PCR products were run on 1.5% agarose gels and stained by ethidium bromide. |
Published data of mRNA expression in normal tissues
ShowTissue | Methodology | PMID |
---|---|---|
Testis | RT-PCR | 8276455 |
Testis | Oligonucleotide microarray | 11751535 |
Testis | RT-PCR | 7927540 |
Fetal keratinocytes | qRT-PCR | 17993289 |
Keratinocytes | qRT-PCR | 17993289 |
Differentiated embryonic stem cells (hESC) | RT-PCR | 18611917 |
Published data of mRNA expression in neoplasias
Brain cancer Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Ependymoma (Pediatric) |
8/14 (57%) | RT-PCR | 10037183 | |
Glioblastoma multiforme |
1/20 (5%) | RT-PCR | ||
Glioblastoma multiforme (Pediatric) |
1/9 (11%) | RT-PCR | ||
Medulloblastoma (Pediatric) |
9/15 (60%) | RT-PCR | ||
Medulloblastoma (Pediatric) |
2/11 (18%) | qRT-PCR | 18398575 |
Hepatobiliary cancer Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Hepatocellular carcinoma |
8/22 (35%) | RT-PCR | 10189127 | |
Hepatocellular carcinoma |
0/4 (0%)(Well differentiated) | RT-PCR | 10568832 | |
Hepatocellular carcinoma |
9/56 (16%)(Mod or poorly differentiated) | RT-PCR |
Lung cancer Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Non small cell lung carcinoma |
13/46 (28%) | RT-PCR | 15201976 | |
Non small cell lung carcinoma |
9/33 (27%) | qRT-PCR | 17066423 | |
Adenocarcinoma |
4/35 (11%) | RT-PCR | 7622303 | |
Large cell carcinoma |
0/1 (0%) | RT-PCR | ||
Small cell lung carcinoma |
0/3 (0%) | RT-PCR | ||
Squamous cell carcinoma |
3/14 (21%) | RT-PCR | ||
Lung carcinoma |
2/12 (16.7%) | Nested RT-PCR | 12133624 | |
Adenocarcinoma |
9/18 (50%) | RT-PCR | 8119772 | |
Large cell carcinoma |
� (50%) | RT-PCR | ||
Small cell lung carcinoma |
2/3 (67%) | RT-PCR | ||
Squamous cell carcinoma |
6/26 (23%) | RT-PCR | ||
Adenocarcinoma |
7/21 (33%) | RT-PCR | 9486785 | |
Adenosquamous carcinoma |
0/2 (0%) | RT-PCR | ||
Small cell lung carcinoma |
0/1 (0%) | RT-PCR | ||
Squamous cell carcinoma |
6/18 (33%) | RT-PCR | ||
Adenocarcinoma |
34/38 (89%) | c-DNA microarray | 17208331 | |
Squamous cell carcinoma |
12/14 (86%) | c-DNA microarray | ||
Adenocarcinoma |
1/29 (3%) | RT-PCR | 22138038 | |
Squamous cell carcinoma |
0/29 (0%) | RT-PCR |
Melanocytic lesion Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Melanoma |
6/10 (60%) | Nested RT-PCR | 12190937 | |
"In situ" melanoma |
0/3 (0%) | RT-PCR | 10215777 | |
Benign melanocytic nevus |
0/10 (0%) | RT-PCR | ||
Dysplastic nevus |
0/14 (0%) | RT-PCR | ||
Melanoma |
Metastatic tumor | 0/3 (0%) | RT-PCR | |
Melanoma |
Primary tumor | 0/4 (0%) | RT-PCR | |
Benign nevocellular nevus |
0/12 (0%) | RT-PCR | 7591235 | |
Dysplastic nevus |
0/4 (0%) | RT-PCR | ||
Lentigo maligna |
0/4 (0%) | RT-PCR | ||
Melanoma |
Metastatic tumor | 101/145 (70%) | RT-PCR | |
Melanoma |
Primary tumor | 41/100 (41%) | RT-PCR | |
Ocular melanoma |
Primary tumor | 1/1 (100%) | RT-PCR | 9247253 |
Ocular melanoma |
Metastatic tumor | � (75%) | RT-PCR | |
Melanoma |
21/47 (45%) | RT-PCR | 10890380 |
Ovarian cancer Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Serous ovarian adenocarcinoma |
4/19 (21%) | RT-PCR | 8550240 | |
Yolk-sac tumor |
� (25%) | RT-PCR |
Sarcoma Show
Tumor Subtype | Sample type | Frequency | Methodology | PMID |
---|---|---|---|---|
Osteosarcoma |
23/28 (82%) | qRT-PCR | 22009167 |
Published data of mRNA expression in Cell Lines
ShowOrigin tissue | Cell Line ID | Frequency | Methodology | PMID |
---|---|---|---|---|
Adult keratinocyte cell line | NHEK | 1/1 (100%) | RT-PCR | 19358718 |
Breast carcinoma | InLa KS SkBr3 T47D |
4/13 (31%) | RT-PCR | 12836015 |
Breast carcinoma | SUM159 SUM52 SUM225 |
3/12 (25%) | RT-PCR | 16505281 |
Breast carcinoma | BT-20 HBL-HX |
RT-PCR | 8416750 | |
Breast carcinoma | HBL-HX Hs578T |
2/5 (40%) | RT-PCR | 8416750 |
Colon carcinoma | IR806 SW403 |
2/3 (66%) | RT-PCR | 12100028 |
Colon carcinoma | MZ-CO-2 SK-CO-11 HSR 320 |
RT-PCR | 7927540 | |
Colon carcinoma | LB31 | RT-PCR | 1840703 | |
Gastrict carcinoma | SNU-1 SNU-16 SNU-216 SNU-484 SNU-601 |
5/11 (46%) | RT-PCR | 11289403 |
Leukemia | K562 | RT-PCR | 7927540 | |
Lung carcinoma | H209 H345 H510 LB11 LB37 |
RT-PCR | 1840703 | |
Lung carcinoma- NSCLC | UKY-29 NCI-H1650 NCI-H157 NCI-H647 NCI-H661 NCI-H1155 NCI-H1264 NCI-H1299 NCI-H944 |
9/29 (31%) | RT-PCR | 11551413 |
Lung carcinoma- SCLC | LB11 LB1 |
RT-PCR | 7927540 | |
Lung carcinoma- SCLC | OC1 | 1/1 (100%) | Oligonucleotide microarray | 11751535 |
Melanoma | 397-mel 397-R4-mel 501-mel 526-mel 537-mel 553-mel 586-mel 624-mel 677-mel 697-mel 836-mel 938-mel MZ2-mel.43 SK23-mel |
14/17 (82%) | RT-PCR | 8416750 |
Melanoma | 397-mel 397-R4-mel 537-mel 553-mel 624-mel 677-mel MZ2-mel.43 SK23-mel YU SITI |
9/17 (53%) | RT-PCR | 8416750 |
Melanoma | MI10221 MZ2-MEL3.0 |
RT-PCR | 7927540 | |
Melanoma | MZ2.MEL3.0 LB34-MEL M110221-MEL M113443-MEL SK33-MEL SK23-MEL LB17-MEL LB33-MEL MI4024-MEL MZ3-MEL MZ5-MEL |
RT-PCR | 1840703 | |
Melanoma | LB1751-MEL LB373-MEL MZ2-MEL.3.0 LB1448-MEL.2 LB583-MEL.6 LB1781-MEL |
6/9 (67%) | Oligonucleotide microarray | 11751535 |
Melanoma | MZ2-MEL.61D MI-10221-MEL LY2-MEL LY4-MEL SK23-MEL LB34-MEL NA6-MEL MI-13441-MEL LB5-MEL LB33-MEL LB73-MEL |
12/16 (75%) | RT-PCR | 8113684 |
Melanoma | WM115-A WM1972-A WM1976-A WM3130-A |
4/4 (100%) | RT-PCR | 18205182 |
Melanoma | Sk-Mel-37 Sk-Mel-29 Sk-Mel-28 Sk-Mel-24 Malme-3M |
5/5 | RT-PCR | 18395366 |
Melanoma | UKRV-Mel-02 WM98.1 UKRV-Mel-14 UKRV-Mel-20 UKRV-Mel-06 UKRV-Mel-21 UKRV-Mel-31 UKRV-Mel-27 Ma-Mel-13 SK-Mel-23 Ma-Mel-22 UKRV-Mel-12c |
12/24 (50%) | Nested RT-PCR | 12190937 |
Melanoma stem cells (MSC) | WM115-NA WM1972-NA WM1976-NA WM3130-NA |
4/4 (100%) | RT-PCR | 18205182 |
Nullipotent teratocarcinoma | PA-1 | RT-PCR | 21785609 | |
Oral squamous cell carcinoma | PCI13-11 PCI1-1 PCI52 PCI68-1 |
5/5 (100%) | RT-PCR | 19358718 |
Ovarian carcinoma | KlHe | 1/6 (17%) | RT-PCR | 12836015 |
Prostate carcinoma | LNCaP CWR22 |
qRT-PCR | 20583133 | |
Rhabdomyosarcoma (embryonal) | RD |
RT-PCR | 21785609 | |
Thyroid cancer | TT | RT-PCR | 1840703 | |
Thyroid cancer | TT | 1/1 (100%) | Oligonucleotide microarray | 11751535 |
2005-2009© CT Antigens Database